Please login to the form below

Not currently logged in
Email:
Password:

BMS appoints Elliott Sigal to Board

Bristol-Myers Squibb has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee

Bristol-Myers Squibb (BMS) has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee.

Sigal joined BMS in 1997 as vice president of applied genomics. He has since served in critical leadership roles within R&D, including drug discovery and development. During Sigal's time as chief scientific officer, BMS achieved eight new drug approvals and filled the drug pipeline with numerous mid- and late-stage assets, five of which could be approved by 2012. 

"We are very excited to have Elliott join our Board," said James M Cornelius, chairman, Bristol-Myers Squibb. "Under his leadership, our R&D organisation has become one of the most productive in the industry. Today's appointment recognises his great contribution to the company." 
Sigal has held the role of executive vice president, chief scientific officer and president, BMS research and development since 2004. He reports to Lamberto Andreotti, CEO, BMS.

2nd March 2011

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics